profit from every $100 of sales.
$0$100
Larimar Therapeutics
$2.53+5.86% today
-26.9% in 1 year
1-year low $1.991-year high $5.95
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Larimar Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$166 million of profit last year.
SalesProfit
Larimar Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Larimar Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Larimar Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -37 | -42 | -91 | -172 | |
| -36 | -41 | -91 | -172 | |
| -35 | -37 | -81 | -166 | |
| -1.37 | -0.84 | -1.32 | -2.27 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 126 | 96 | 200 | 146 |
| Cash | 27 | 27 | 33 | 85 |
| Total debt | 5 | 6 | 5 | 4 |
| Total liabilities | 16 | 14 | 28 | 68 |
| 111 | 82 | 172 | 78 | |
| 26 | 44 | 61 | 73 | |
| -24.8% | -37.8% | -40.6% | -165.9% | |
| -31.9% | -45.2% | -46.9% | -212.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -28 | -33 | -71 | -113 | |
| 0 | 0 | 1 | 0 | |
| -28 | -34 | -71 | -113 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 7 | 8 | 9 | 7 |
Valuation
- –
- –
- –
- 1.9×
- –
- –
- –
- -43.1%
- -63.0%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -106.6%
- -78.4%
- -134.1%
- -79.6%
- -107.3%
- –
Growth
- –
- –
- −59.0%
- –
- +43.6%
Financial health
- 1.0×
- 0.02
- 1.8%
- –
- 4.29
- 4.29
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 871
Bottom 1%of 985
What analysts expect
- Average price target
- $12.00
- Range
- $12.00 – $12.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.31 | -0.53 | +41.5% |
| Mar 19, 2026 | -0.73 | -0.44 | −65.9% |
| Nov 5, 2025 | -0.61 | -0.39 | −56.4% |
| Aug 14, 2025 | -0.41 | -0.47 | +12.8% |
| Apr 30, 2025 | -0.46 | -0.42 | −9.5% |
| Mar 24, 2025 | -0.45 | -0.29 | −55.2% |
| Oct 30, 2024 | -0.24 | -0.37 | +35.1% |
| Aug 7, 2024 | -0.34 | -0.32 | −6.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
18No pass
Benjamin Graham
55No pass
Philip Fisher
30No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
23No pass
Terry Smith
19No pass
Questions about Larimar Therapeutics
Is Larimar Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Larimar Therapeutics AI analysis
What does Larimar Therapeutics do?
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. It is in Biotechnology.
Does Larimar Therapeutics pay a dividend?
No. Larimar Therapeutics does not pay a dividend at the moment.
Is Larimar Therapeutics stock halal?
Questionable. Larimar Therapeutics sits in a grey zone: its cash and confirmed interest-bearing investments are 33% of its market value, between 30% and 33%. How we check
How has Larimar Therapeutics stock done over the past year?
Down 26.9% over the past twelve months, to $2.53. It traded between $1.99 and $5.95 and is 57.5% below its high.
Who are Larimar Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Larimar Therapeutics's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.